Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v14.i1.40
pages 57-77

Role for the cAMP-Protein Kinase A Signaling Pathway in Suppression of Antitumor Immune Responses by Regulatory T Cells

Sheraz Yaqub
The Biotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo; and Department of Gastroenterological Surgery, Akershus University Hospital, N-1478 Lørenskog, Norway
Kjetil Tasken
The Biotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, Norway

ABSTRAKT

CD4+CD25+ regulatory T (Treg) cells are engaged in the maintenance of immunological self-tolerance and suppressive control of excessive immune responses to foreign antigens. Furthermore, Treg cells infiltrate tumor tissues and may impede immune surveillance against cancer and hamper the development of an effective antitumor immunity. Depletion of Treg cells in animal models has been demonstrated to provoke tumor immunity. Attenuation of Treg-mediated suppression is therefore an interesting strategy to enhance antitumor responses. We recently found that adaptive Treg cells express COX-2 and suppress responder T cells in a PGE2-cAMP-dependent manner, which can be reversed by COX-2 inhibitors or EP-receptor antagonists. The same mechanism also appeared to be operative in patients with colorectal cancer where treatment with COX-inhibitor or cAMP-antagonist enhanced antitumor immune responses to the same extent as depletion of Treg cells. This provides mechanism-based opportunities for pharmacological intervention to interfere with Treg immunosuppression. In this review we will discuss key mechanisms used by Treg cells to suppress antitumor immunity, with emphasis on the cAMP-PKA pathway. We will also highlight some of the roles of Treg cells in cancer.


Articles with similar content:

Strategies to enhance NK cell function for the treatment of tumors and infections
Critical Reviews™ in Immunology, Vol.38, 2018, issue 2
Taku Kambayashi, Jacquelyn Freund-Brown, Leilani Chirino
Modulation of Immune Responses by Histone Deacetylase Inhibitors
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Heiko Brennenstuhl, Ulrike Naumann, Sonja Schotterl
Immunologic Nonresponsiveness to Tumors
Critical Reviews™ in Oncogenesis, Vol.9, 1998, issue 1
Martine Extermann, Scott J. Antonia, Richard A. Flavell
Tumor Plasticity Interferes with Anti-Tumor Immunity
Critical Reviews™ in Immunology, Vol.34, 2014, issue 2
Andres Tittarelli, Salem Chouaib, Jean Paul Thiery, Bassam Janji, Alexander Eggermont
Transcriptional Regulation of IL-10 and Its Cell-Specific Role In Vivo
Critical Reviews™ in Immunology, Vol.34, 2014, issue 4
J. Simon C. Arthur, Kirsty F. MacKenzie, Michael J. Pattison